RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer
CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results
Merus Labs Appoints New Director and Provides European Update
S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.
Investors Scoop Up Companies' Bonds
Asahi Kasei Pharma Selects Evotec as Its Partner for Ion Channel Drug Discovery